Prognostic and predictive role of EGFR pathway alterations in biliary cancer patients treated with chemotherapy and anti-EGFR-Reference-Cited by-同舟云学术

Prognostic and predictive role of EGFR pathway alterations in biliary cancer patients treated with chemotherapy and anti-EGFR

Published:2018-01-19 Issue:1 Volume:13 Page:e0191593
ISSN:1932-6203
Container-title:PLOS ONE
language:en
Short-container-title:PLoS ONE

Author:

Peraldo-Neia Caterina^ORCID,Cavalloni Giuliana,Fenocchio Elisabetta,Cagnazzo Celeste,Gammaitoni Loretta,Cereda Stefano,Nasti Guglielmo,Satolli Maria Antonietta,Aprile Giuseppe,Reni Michele,Avallone Antonio,Spadi Rosella,Venesio Tiziana,Martin Vittoria,Doglioni Claudio,Frattini Milo,Aglietta Massimo,Leone Francesco

Publisher

Public Library of Science (PLoS)

Subject

Multidisciplinary

Reference45 articles.

1. Randomized phase II study of gefitinib compared with placebo in chemotherapy-naive patients with advanced non-small-cell lung cancer and poor performance status;G Goss;J Clin Oncol,2009

2. Anti-epidermal-growth-factor-receptor agents and complete responses in the treatment of advanced non-small-cell lung cancer: a meta-analysis of 17 phase III randomized controlled trials;WX Qi;Curr Med Res Opin,2015

3. Efficacy of epidermal growth factor receptor inhibitors versus chemotherapy as second-line treatment in advanced non-small-cell lung cancer with wild-type EGFR: a meta-analysis of randomized controlled clinical trials;N Zhao;Lung Cancer,2014

4. Gefitinib or Erlotinib vs Chemotherapy for EGFR Mutation-Positive Lung Cancer: Individual Patient Data Meta-Analysis of Overall Survival;CK Lee;J Natl Cancer Inst,2017

5. Meta-analysis: the efficacy and safety of monoclonal antibody targeted to epidermal growth factor receptor in the treatment of patients with metastatic colorectal cancer;F Nie;J Dig Dis,2009

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Bevacizumab Erlotinib Switch Maintenance in Chemo-Responsive Advanced Gallbladder and Cholangiocarcinoma (BEER BTC): A Multicenter, Open-Label, Randomized, Phase II Trial;Journal of Clinical Oncology;2024-08-05

2. TNIK drives castration-resistant prostate cancer via phosphorylating EGFR;iScience;2024-01

3. Methodical selected coptisine attenuates the malignancy of cholangiocarcinoma through the blockade of EGFR signalling;Journal of Functional Foods;2024-01

4. Genetic alterations shaping tumor response to anti-EGFR therapies;Drug Resistance Updates;2022-09

5. Heterogeneity of resistant mechanisms in an EGFR-TKI relapsed patient with EGFR amplification and response to nimotuzumab: A case report;FRONT ONCOL;2022